{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-399378","form_type":"8-K","ticker":"EVMN","cik":"0002044725","company_name":"Evommune, Inc.","filed_at":"2026-09-23T20:05:30+00:00","discovered_at":"2026-09-23T20:06:00.271886+00:00","generated_at":"2026-09-23T20:06:43.033954+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Evommune to present Phase 2a EVO301 AD data at EADV 2026; Phase 2b planned mid-2027","bullets":["Phase 2a EVO301 (IL-18 binding protein) atopic dermatitis data in late-breaker Oct 1 at EADV Vienna; presenter Dr. Mark G. Lebwohl.","Topline results previously reported this year; Phase 2b dose-ranging study in moderate-to-severe AD expected to start mid-2027.","EVO301 targets IL-18 upstream of Th2 axis, modulating Th1, Th2, Th17/22 and innate inflammatory pathways.","CEO Luis Peña cites 29M patients in 7 major markets needing advanced AD therapy; IL-18 offers broad-spectrum potential."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-399378","json":"https://secwatch.observer/filing/0001193125-26-399378.json","markdown":"https://secwatch.observer/filing/0001193125-26-399378.md","text":"https://secwatch.observer/filing/0001193125-26-399378.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/0001193125-26-399378-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2044725/000119312526399378/evmn-20260923.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-23T20:06:43.033954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}